SK12342000A3 - Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie - Google Patents

Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie Download PDF

Info

Publication number: SK12342000A3
Authority: SK; Slovakia
Prior art keywords: mono; alkyl; carbon atoms; compound; pharmaceutically acceptable
Prior art date: 1998-02-27

Application number

SK1234-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Ernest S. Hamanaka

Angel Guzman-Perez

Roger B. Ruggeri

Ronald T. Wester

Christian J. Mularski

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-27

Filing date

1999-02-05

Publication date

2001-03-12

1999-02-05 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2001-03-12 Publication of SK12342000A3 publication Critical patent/SK12342000A3/sk

Links

208000028867 ischemia Diseases 0.000 title claims abstract description 33
150000002357 guanidines Chemical class 0.000 title description 6
229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 5
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title description 3
238000000034 method Methods 0.000 claims abstract description 114
230000000451 tissue damage Effects 0.000 claims abstract description 31
231100000827 tissue damage Toxicity 0.000 claims abstract description 31
239000003112 inhibitor Substances 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
150000001875 compounds Chemical class 0.000 claims description 522
125000000217 alkyl group Chemical group 0.000 claims description 490
229910052757 nitrogen Inorganic materials 0.000 claims description 486
125000004432 carbon atom Chemical group C* 0.000 claims description 467
-1 cyano, thio Chemical group 0.000 claims description 410
150000003839 salts Chemical class 0.000 claims description 268
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 195
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 142
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 119
229920006395 saturated elastomer Polymers 0.000 claims description 115
229910052799 carbon Inorganic materials 0.000 claims description 114
125000000753 cycloalkyl group Chemical group 0.000 claims description 110
125000003545 alkoxy group Chemical group 0.000 claims description 100
229910052760 oxygen Inorganic materials 0.000 claims description 97
229940002612 prodrug Drugs 0.000 claims description 96
239000000651 prodrug Substances 0.000 claims description 96
125000001153 fluoro group Chemical group F* 0.000 claims description 92
125000005842 heteroatom Chemical group 0.000 claims description 91
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 90
229910052717 sulfur Inorganic materials 0.000 claims description 90
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 89
239000001301 oxygen Substances 0.000 claims description 89
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 84
239000011593 sulfur Chemical group 0.000 claims description 84
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 78
125000002619 bicyclic group Chemical group 0.000 claims description 77
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 76
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 73
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 67
125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 66
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 65
125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 64
229910052736 halogen Inorganic materials 0.000 claims description 64
125000004414 alkyl thio group Chemical group 0.000 claims description 63
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 61
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 61
150000002367 halogens Chemical class 0.000 claims description 57
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 55
210000001519 tissue Anatomy 0.000 claims description 55
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 49
125000001424 substituent group Chemical group 0.000 claims description 49
241000124008 Mammalia Species 0.000 claims description 44
229910052739 hydrogen Inorganic materials 0.000 claims description 44
239000001257 hydrogen Substances 0.000 claims description 44
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 43
125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 41
239000000203 mixture Substances 0.000 claims description 41
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 40
FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 claims description 40
230000000302 ischemic effect Effects 0.000 claims description 39
125000002252 acyl group Chemical group 0.000 claims description 37
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 37
125000003282 alkyl amino group Chemical group 0.000 claims description 36
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 35
210000002216 heart Anatomy 0.000 claims description 35
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 29
239000003937 drug carrier Substances 0.000 claims description 28
239000002552 dosage form Substances 0.000 claims description 27
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
150000001721 carbon Chemical group 0.000 claims description 26
125000004093 cyano group Chemical group *C#N 0.000 claims description 26
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 26
125000004423 acyloxy group Chemical group 0.000 claims description 24
125000005236 alkanoylamino group Chemical group 0.000 claims description 24
239000003085 diluting agent Substances 0.000 claims description 24
239000003288 aldose reductase inhibitor Substances 0.000 claims description 23
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 23
125000004076 pyridyl group Chemical group 0.000 claims description 23
230000001225 therapeutic effect Effects 0.000 claims description 23
239000011230 binding agent Substances 0.000 claims description 22
239000003795 chemical substances by application Substances 0.000 claims description 22
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 21
125000005843 halogen group Chemical group 0.000 claims description 20
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 20
125000000714 pyrimidinyl group Chemical group 0.000 claims description 20
125000004429 atom Chemical group 0.000 claims description 19
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 19
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 19
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 19
238000001356 surgical procedure Methods 0.000 claims description 19
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 18
229940118148 Aldose reductase inhibitor Drugs 0.000 claims description 18
125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 18
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 18
125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 17
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 17
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 16
125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 16
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 16
ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims description 15
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
239000002327 cardiovascular agent Substances 0.000 claims description 14
229940125692 cardiovascular agent Drugs 0.000 claims description 14
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 13
210000000056 organ Anatomy 0.000 claims description 13
125000003884 phenylalkyl group Chemical group 0.000 claims description 13
230000006378 damage Effects 0.000 claims description 12
125000000392 cycloalkenyl group Chemical group 0.000 claims description 11
125000001041 indolyl group Chemical class 0.000 claims description 11
125000001624 naphthyl group Chemical group 0.000 claims description 11
125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 10
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 10
125000000623 heterocyclic group Chemical group 0.000 claims description 10
125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
125000002950 monocyclic group Chemical group 0.000 claims description 10
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 9
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims description 9
230000000747 cardiac effect Effects 0.000 claims description 9
238000007675 cardiac surgery Methods 0.000 claims description 9
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 9
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 8
125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 8
210000004556 brain Anatomy 0.000 claims description 8
150000002148 esters Chemical class 0.000 claims description 8
229910052731 fluorine Inorganic materials 0.000 claims description 8
235000019000 fluorine Nutrition 0.000 claims description 8
239000001103 potassium chloride Substances 0.000 claims description 8
235000011164 potassium chloride Nutrition 0.000 claims description 8
239000003379 purinergic P1 receptor agonist Substances 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 7
230000000968 intestinal effect Effects 0.000 claims description 7
238000002054 transplantation Methods 0.000 claims description 7
WSLKLYKPUZWAQW-UHFFFAOYSA-N 5-cyclopropyl-1-quinolin-5-ylpyrazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2)C=1C1CC1 WSLKLYKPUZWAQW-UHFFFAOYSA-N 0.000 claims description 6
ZEDQLIICZORELY-UHFFFAOYSA-N 5-methyl-1-quinolin-6-ylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=CC=C(N=CC=C2)C2=C1 ZEDQLIICZORELY-UHFFFAOYSA-N 0.000 claims description 6
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 claims description 6
229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
229960005305 adenosine Drugs 0.000 claims description 6
125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
210000005003 heart tissue Anatomy 0.000 claims description 6
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 5
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 5
125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 claims description 5
CNAUCBNUTUGRDC-UHFFFAOYSA-N 5-cyclopropyl-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NN(C=2C(=CC=CC=2)C(F)(F)F)C=1C1CC1 CNAUCBNUTUGRDC-UHFFFAOYSA-N 0.000 claims description 5
NWYHYJVRSBVTGC-UHFFFAOYSA-N 5-ethyl-1-quinolin-5-ylpyrazole-4-carboxylic acid Chemical compound CCC1=C(C(O)=O)C=NN1C1=CC=CC2=NC=CC=C12 NWYHYJVRSBVTGC-UHFFFAOYSA-N 0.000 claims description 5
239000005541 ACE inhibitor Substances 0.000 claims description 5
229940127291 Calcium channel antagonist Drugs 0.000 claims description 5
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 5
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
125000000304 alkynyl group Chemical group 0.000 claims description 5
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
239000000480 calcium channel blocker Substances 0.000 claims description 5
229960002896 clonidine Drugs 0.000 claims description 5
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 5
229960002768 dipyridamole Drugs 0.000 claims description 5
239000002934 diuretic Substances 0.000 claims description 5
239000011737 fluorine Substances 0.000 claims description 5
229930182470 glycoside Natural products 0.000 claims description 5
150000002338 glycosides Chemical class 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
208000037891 myocardial injury Diseases 0.000 claims description 5
GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims description 5
229960002816 potassium chloride Drugs 0.000 claims description 5
HYNXFOPOJQHNAI-UHFFFAOYSA-N 1-isoquinolin-5-yl-3-methylpyrazole-4-carboxylic acid Chemical compound C1=C(C(O)=O)C(C)=NN1C1=CC=CC2=CN=CC=C12 HYNXFOPOJQHNAI-UHFFFAOYSA-N 0.000 claims description 4
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 4
GZILZCCGDNKAAV-UHFFFAOYSA-N 5-chloro-1h-indole-2-carboxamide Chemical compound ClC1=CC=C2NC(C(=O)N)=CC2=C1 GZILZCCGDNKAAV-UHFFFAOYSA-N 0.000 claims description 4
GOZINTPHLXUATQ-UHFFFAOYSA-N 5-cyclopropyl-1-quinolin-8-ylpyrazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NN(C=2C3=NC=CC=C3C=CC=2)C=1C1CC1 GOZINTPHLXUATQ-UHFFFAOYSA-N 0.000 claims description 4
LFXTUZDNFLZCNR-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)C(F)(F)F)C=1C1CC1 LFXTUZDNFLZCNR-UHFFFAOYSA-N 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 4
210000004185 liver Anatomy 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 4
230000002207 retinal effect Effects 0.000 claims description 4
210000002027 skeletal muscle Anatomy 0.000 claims description 4
210000000952 spleen Anatomy 0.000 claims description 4
230000002537 thrombolytic effect Effects 0.000 claims description 4
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 3
IWLPHHUXVUATBQ-UHFFFAOYSA-N 2-isoquinolin-5-yl-5-methyltriazole-4-carboxylic acid Chemical compound N1=C(C(O)=O)C(C)=NN1C1=CC=CC2=CN=CC=C12 IWLPHHUXVUATBQ-UHFFFAOYSA-N 0.000 claims description 3
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 3
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
HDPFDIUJHFATNN-UHFFFAOYSA-N 5-methyl-1-naphthalen-1-ylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=CC=CC2=CC=CC=C12 HDPFDIUJHFATNN-UHFFFAOYSA-N 0.000 claims description 3
XAMARBFYCUIBJA-UHFFFAOYSA-N 5-methyl-2-naphthalen-1-yltriazole-4-carboxylic acid Chemical compound N1=C(C(O)=O)C(C)=NN1C1=CC=CC2=CC=CC=C12 XAMARBFYCUIBJA-UHFFFAOYSA-N 0.000 claims description 3
ILKNSPWBNNHYMC-UHFFFAOYSA-N 5-methyl-2-quinolin-5-yltriazole-4-carboxylic acid Chemical compound N1=C(C(O)=O)C(C)=NN1C1=CC=CC2=NC=CC=C12 ILKNSPWBNNHYMC-UHFFFAOYSA-N 0.000 claims description 3
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 3
SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims description 3
239000002876 beta blocker Substances 0.000 claims description 3
229940097320 beta blocking agent Drugs 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
229960001289 prazosin Drugs 0.000 claims description 3
229960000103 thrombolytic agent Drugs 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
125000006709 (C5-C7) cycloalkenyl group Chemical group 0.000 claims description 2
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
YZLNQKMWEXOAPY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-phenylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=CC=CC=2)C=1C1CC1 YZLNQKMWEXOAPY-UHFFFAOYSA-N 0.000 claims description 2
125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 2
210000005013 brain tissue Anatomy 0.000 claims description 2
NRQBHARHWSTOEU-UHFFFAOYSA-N ethyl 5-cyclopropyl-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C=2C(=CC=CC=2)C(F)(F)F)C=1C1CC1 NRQBHARHWSTOEU-UHFFFAOYSA-N 0.000 claims description 2
GCSSMQVYMINFEI-UHFFFAOYSA-N ethyl 5-cyclopropyl-1-quinolin-8-ylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C=2C3=NC=CC=C3C=CC=2)C=1C1CC1 GCSSMQVYMINFEI-UHFFFAOYSA-N 0.000 claims description 2
ZTSMDLWTSJDXDJ-UHFFFAOYSA-N ethyl 5-methyl-1-naphthalen-1-ylpyrazole-4-carboxylate Chemical compound CC1=C(C(=O)OCC)C=NN1C1=CC=CC2=CC=CC=C12 ZTSMDLWTSJDXDJ-UHFFFAOYSA-N 0.000 claims description 2
IDZKPWASEWZONA-UHFFFAOYSA-N ethyl 5-methyl-1-quinolin-6-ylpyrazole-4-carboxylate Chemical compound CC1=C(C(=O)OCC)C=NN1C1=CC=C(N=CC=C2)C2=C1 IDZKPWASEWZONA-UHFFFAOYSA-N 0.000 claims description 2
210000005228 liver tissue Anatomy 0.000 claims description 2
DIDVCLKJLFLTTI-UHFFFAOYSA-N methyl 5-ethyl-1-quinolin-5-ylpyrazole-4-carboxylate Chemical compound CCC1=C(C(=O)OC)C=NN1C1=CC=CC2=NC=CC=C12 DIDVCLKJLFLTTI-UHFFFAOYSA-N 0.000 claims description 2
QRZKFORTHOZDTO-UHFFFAOYSA-N n-(diaminomethylidene)-3-methyl-1-phenylpyrazole-4-carboxamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC=C1 QRZKFORTHOZDTO-UHFFFAOYSA-N 0.000 claims description 2
GSKLXGZWPHJZHX-UHFFFAOYSA-N n-(diaminomethylidene)-4-methyl-1-phenylpyrazole-3-carboxamide Chemical compound N1=C(C(=O)NC(N)=N)C(C)=CN1C1=CC=CC=C1 GSKLXGZWPHJZHX-UHFFFAOYSA-N 0.000 claims description 2
WXRXSMMKVWZIFU-UHFFFAOYSA-N n-(diaminomethylidene)-5-methyl-2-naphthalen-1-yltriazole-4-carboxamide Chemical compound N1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC2=CC=CC=C12 WXRXSMMKVWZIFU-UHFFFAOYSA-N 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims description 2
210000001032 spinal nerve Anatomy 0.000 claims description 2
229940124530 sulfonamide Drugs 0.000 claims description 2
150000003456 sulfonamides Chemical class 0.000 claims description 2
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 4
229910002651 NO3 Inorganic materials 0.000 claims 3
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 3
239000002593 adenosine A3 receptor agonist Substances 0.000 claims 3
230000001882 diuretic effect Effects 0.000 claims 3
239000008024 pharmaceutical diluent Substances 0.000 claims 3
NQRLUVCEUCAHST-UHFFFAOYSA-N 1-chloroindole-2-carboxylic acid Chemical compound C1=CC=C2N(Cl)C(C(=O)O)=CC2=C1 NQRLUVCEUCAHST-UHFFFAOYSA-N 0.000 claims 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
239000003146 anticoagulant agent Substances 0.000 claims 2
239000012964 benzotriazole Substances 0.000 claims 2
239000003527 fibrinolytic agent Substances 0.000 claims 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
239000008014 pharmaceutical binder Substances 0.000 claims 2
239000004036 potassium channel stimulating agent Substances 0.000 claims 2
125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 claims 1
VGJIXQLEZJZTAO-UHFFFAOYSA-N 1-(5-methylnaphthalen-1-yl)pyrazole-4-carboxylic acid Chemical compound C1=CC=C2C(C)=CC=CC2=C1N1C=C(C(O)=O)C=N1 VGJIXQLEZJZTAO-UHFFFAOYSA-N 0.000 claims 1
NIBFJPXGNVPNHK-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-4-carbaldehyde Chemical group C1=CC(C=O)=C2OC(F)(F)OC2=C1 NIBFJPXGNVPNHK-UHFFFAOYSA-N 0.000 claims 1
WAAVFJWSRFFSSW-BETUJISGSA-N 5-chloro-n-[2-[(3s,4r)-3,4-dihydroxypyrrolidin-1-yl]-2-oxoethyl]-1h-indole-2-carboxamide Chemical compound C1[C@@H](O)[C@@H](O)CN1C(=O)CNC(=O)C1=CC2=CC(Cl)=CC=C2N1 WAAVFJWSRFFSSW-BETUJISGSA-N 0.000 claims 1
LGOPZILIFLMNPA-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,3-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=C(Cl)C=CC=2)Cl)C=1C1CC1 LGOPZILIFLMNPA-UHFFFAOYSA-N 0.000 claims 1
NVPIIEFYJSAEED-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,5-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=C(Cl)C=2)Cl)C=1C1CC1 NVPIIEFYJSAEED-UHFFFAOYSA-N 0.000 claims 1
229940123934 Reductase inhibitor Drugs 0.000 claims 1
125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 1
125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
125000002947 alkylene group Chemical group 0.000 claims 1
KDRWXCMGMPBUFQ-UHFFFAOYSA-N ethyl 5-cyclopropyl-1-quinolin-5-ylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2)C=1C1CC1 KDRWXCMGMPBUFQ-UHFFFAOYSA-N 0.000 claims 1
229910052602 gypsum Inorganic materials 0.000 claims 1
239000010440 gypsum Substances 0.000 claims 1
AVBATQOBXIRWGX-UHFFFAOYSA-N n-(diaminomethylidene)-1-(1h-indazol-7-yl)-3-methylpyrazole-4-carboxamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC2=C1NN=C2 AVBATQOBXIRWGX-UHFFFAOYSA-N 0.000 claims 1
YMOWZLQWXFQPQL-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-naphthalen-1-ylpyrazole-3-carboxamide Chemical compound C1=C(C(=O)NC(N)=N)N(C)N=C1C1=CC=CC2=CC=CC=C12 YMOWZLQWXFQPQL-UHFFFAOYSA-N 0.000 claims 1
ZHHBBKBQTKYXIS-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-phenylpyrazole-3-carboxamide Chemical compound C1=C(C(=O)NC(N)=N)N(C)N=C1C1=CC=CC=C1 ZHHBBKBQTKYXIS-UHFFFAOYSA-N 0.000 claims 1
150000002926 oxygen Chemical class 0.000 claims 1
210000000496 pancreas Anatomy 0.000 claims 1
210000004923 pancreatic tissue Anatomy 0.000 claims 1
150000003254 radicals Chemical class 0.000 claims 1
125000000547 substituted alkyl group Chemical group 0.000 claims 1
102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 abstract description 7
108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 abstract description 7
230000009467 reduction Effects 0.000 abstract description 4
229960004198 guanidine Drugs 0.000 description 44
150000002431 hydrogen Chemical class 0.000 description 25
241000282414 Homo sapiens Species 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
238000012360 testing method Methods 0.000 description 21
208000010125 myocardial infarction Diseases 0.000 description 19
239000002904 solvent Substances 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
230000005961 cardioprotection Effects 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
230000002107 myocardial effect Effects 0.000 description 12
230000004224 protection Effects 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
125000002541 furyl group Chemical group 0.000 description 11
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
230000010410 reperfusion Effects 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
208000029078 coronary artery disease Diseases 0.000 description 9
201000010099 disease Diseases 0.000 description 9
239000011734 sodium Substances 0.000 description 9
206010003119 arrhythmia Diseases 0.000 description 8
230000006793 arrhythmia Effects 0.000 description 8
239000002585 base Substances 0.000 description 8
210000004351 coronary vessel Anatomy 0.000 description 8
239000003814 drug Substances 0.000 description 8
125000002883 imidazolyl group Chemical group 0.000 description 8
230000001939 inductive effect Effects 0.000 description 8
125000001786 isothiazolyl group Chemical group 0.000 description 8
125000000842 isoxazolyl group Chemical group 0.000 description 8
125000003373 pyrazinyl group Chemical group 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
125000001544 thienyl group Chemical group 0.000 description 8
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 7
XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 7
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
239000012442 inert solvent Substances 0.000 description 7
210000004165 myocardium Anatomy 0.000 description 7
125000002971 oxazolyl group Chemical group 0.000 description 7
125000003226 pyrazolyl group Chemical group 0.000 description 7
125000000168 pyrrolyl group Chemical group 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
125000000335 thiazolyl group Chemical group 0.000 description 7
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
102000007390 Glycogen Phosphorylase Human genes 0.000 description 6
108010046163 Glycogen Phosphorylase Proteins 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
208000006011 Stroke Diseases 0.000 description 6
230000001476 alcoholic effect Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000004087 circulation Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
125000002757 morpholinyl group Chemical group 0.000 description 6
125000002098 pyridazinyl group Chemical group 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000010186 staining Methods 0.000 description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
229920002527 Glycogen Polymers 0.000 description 5
241000282412 Homo Species 0.000 description 5
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
239000000010 aprotic solvent Substances 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
239000008103 glucose Substances 0.000 description 5
229940096919 glycogen Drugs 0.000 description 5
230000002530 ischemic preconditioning effect Effects 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
125000004193 piperazinyl group Chemical group 0.000 description 5
125000003386 piperidinyl group Chemical group 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
102000016912 Aldehyde Reductase Human genes 0.000 description 4
108010053754 Aldehyde reductase Proteins 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
101000702479 Homo sapiens Sodium/hydrogen exchanger 1 Proteins 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
206010020880 Hypertrophy Diseases 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
238000009835 boiling Methods 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000007887 coronary angioplasty Methods 0.000 description 4
206010020718 hyperplasia Diseases 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
208000037906 ischaemic injury Diseases 0.000 description 4
210000003657 middle cerebral artery Anatomy 0.000 description 4
230000003680 myocardial damage Effects 0.000 description 4
208000031225 myocardial ischemia Diseases 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
125000004043 oxo group Chemical group O=* 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 4
125000002755 pyrazolinyl group Chemical group 0.000 description 4
125000000719 pyrrolidinyl group Chemical group 0.000 description 4
238000011084 recovery Methods 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
238000007631 vascular surgery Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229910052727 yttrium Inorganic materials 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 3
206010002388 Angina unstable Diseases 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
206010007572 Cardiac hypertrophy Diseases 0.000 description 3
208000006029 Cardiomegaly Diseases 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
102100022897 Sodium/hydrogen exchanger 10 Human genes 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000007814 Unstable Angina Diseases 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
208000011775 arteriosclerosis disease Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
208000029028 brain injury Diseases 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
229960003132 halothane Drugs 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
238000000099 in vitro assay Methods 0.000 description 3
201000004332 intermediate coronary syndrome Diseases 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000005240 left ventricle Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
229960001412 pentobarbital Drugs 0.000 description 3
230000002265 prevention Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
208000005069 pulmonary fibrosis Diseases 0.000 description 3
125000003072 pyrazolidinyl group Chemical group 0.000 description 3
229930195734 saturated hydrocarbon Natural products 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 2
125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 2
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
LKBFFDOJUKLQNY-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1F LKBFFDOJUKLQNY-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical group O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 2
PTVBGVLITQPZTD-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,6-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2Cl)Cl)C=1C1CC1 PTVBGVLITQPZTD-UHFFFAOYSA-N 0.000 description 2
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 2
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
108010061435 Enalapril Proteins 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
229940127315 Potassium Channel Openers Drugs 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
RGTGNSLGFMHBDM-UHFFFAOYSA-J [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RGTGNSLGFMHBDM-UHFFFAOYSA-J 0.000 description 2
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
229960002122 acebutolol Drugs 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000004422 alkyl sulphonamide group Chemical group 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
208000008784 apnea Diseases 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
229960002274 atenolol Drugs 0.000 description 2
125000005605 benzo group Chemical group 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
150000001733 carboxylic acid esters Chemical class 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
229960000873 enalapril Drugs 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
230000001434 glomerular Effects 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
210000003128 head Anatomy 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
150000007857 hydrazones Chemical class 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
229960003827 isosorbide mononitrate Drugs 0.000 description 2
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
229910003002 lithium salt Inorganic materials 0.000 description 2
159000000002 lithium salts Chemical class 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960003134 mepindolol Drugs 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
229960003746 metildigoxin Drugs 0.000 description 2
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
229960004255 nadolol Drugs 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
201000009925 nephrosclerosis Diseases 0.000 description 2
150000002823 nitrates Chemical class 0.000 description 2
229960005425 nitrendipine Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
230000008447 perception Effects 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
229960002508 pindolol Drugs 0.000 description 2
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
150000003217 pyrazoles Chemical class 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
239000000523 sample Substances 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
230000009092 tissue dysfunction Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
150000003852 triazoles Chemical class 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 2
229950005346 zopolrestat Drugs 0.000 description 2
JCZPOYAMKJFOLA-IMJSIDKUSA-N (3s,4s)-pyrrolidine-3,4-diol Chemical compound O[C@H]1CNC[C@@H]1O JCZPOYAMKJFOLA-IMJSIDKUSA-N 0.000 description 1
125000004758 (C1-C4) alkoxyimino group Chemical group 0.000 description 1
125000006527 (C1-C5) alkyl group Chemical class 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
PIINXYKJQGMIOZ-UHFFFAOYSA-N 1,2-dipyridin-2-ylethane-1,2-dione Chemical compound C=1C=CC=NC=1C(=O)C(=O)C1=CC=CC=N1 PIINXYKJQGMIOZ-UHFFFAOYSA-N 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
HGOICVLVWODJMV-UHFFFAOYSA-N 1-(2,1,3-benzothiadiazol-4-yl)-n-(diaminomethylidene)-3-methylpyrazole-4-carboxamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC2=NSN=C12 HGOICVLVWODJMV-UHFFFAOYSA-N 0.000 description 1
ZJQFENWMXOATQM-UHFFFAOYSA-N 1-(2-chloro-4-methylsulfonylphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1N1C(C2CC2)=C(C(=O)NC(N)=N)C=N1 ZJQFENWMXOATQM-UHFFFAOYSA-N 0.000 description 1
KWCPQPFOPUCWPH-UHFFFAOYSA-N 1-(oxomethylidene)guanidine Chemical group NC(=N)N=C=O KWCPQPFOPUCWPH-UHFFFAOYSA-N 0.000 description 1
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
HQMDTNPGJUCYMV-UHFFFAOYSA-N 1-[2-chloro-4-(methylsulfamoyl)phenyl]-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound ClC1=CC(S(=O)(=O)NC)=CC=C1N1C(C2CC2)=C(C(=O)NC(N)=N)C=N1 HQMDTNPGJUCYMV-UHFFFAOYSA-N 0.000 description 1
125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
DYAOOYAQOGVEMJ-UHFFFAOYSA-N 2,7-difluoro-4-methoxyspiro[fluorene-9,4'-imidazolidine] Chemical compound COc1cc(F)cc2c1-c1ccc(F)cc1C21CNCN1 DYAOOYAQOGVEMJ-UHFFFAOYSA-N 0.000 description 1
XSAHIDFKNYIJPY-UHFFFAOYSA-N 2,7-difluorospiro[fluorene-9,4'-imidazolidine] Chemical compound Fc1ccc2-c3ccc(F)cc3C3(CNCN3)c2c1 XSAHIDFKNYIJPY-UHFFFAOYSA-N 0.000 description 1
NLFAETJTZKBPJL-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(diaminomethylidene)-5-methyltriazole-4-carboxamide Chemical compound N1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC(Br)=C1 NLFAETJTZKBPJL-UHFFFAOYSA-N 0.000 description 1
FTPBFNMYCGQFGU-UHFFFAOYSA-N 2-[3-[(5,7-dichloro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC(Cl)=C2O1 FTPBFNMYCGQFGU-UHFFFAOYSA-N 0.000 description 1
KNWXUWPPDTZSFW-UHFFFAOYSA-N 2-[3-[(5,7-difluoro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC(F)=C2S1 KNWXUWPPDTZSFW-UHFFFAOYSA-N 0.000 description 1
GDULRSFIHLMHJW-UHFFFAOYSA-N 2-[3-[(5,7-difluoro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC(F)=C2O1 GDULRSFIHLMHJW-UHFFFAOYSA-N 0.000 description 1
LURVWPRCGVAWKT-UHFFFAOYSA-N 2-[3-[(5-chloro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC=C2O1 LURVWPRCGVAWKT-UHFFFAOYSA-N 0.000 description 1
QUBABKJOUGUHAK-UHFFFAOYSA-N 2-[3-[(5-fluoro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC=C2S1 QUBABKJOUGUHAK-UHFFFAOYSA-N 0.000 description 1
DGCTZGDPGOMMNB-UHFFFAOYSA-N 2-[3-oxo-2,8-di(propan-2-yl)-1,4-benzoxazin-4-yl]acetic acid Chemical compound C1=CC=C2N(CC(O)=O)C(=O)C(C(C)C)OC2=C1C(C)C DGCTZGDPGOMMNB-UHFFFAOYSA-N 0.000 description 1
BUYWFAJWTSIACV-UHFFFAOYSA-N 2-[3-oxo-4-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]-1,4-benzothiazin-2-yl]acetic acid Chemical compound FC1=CC(F)=C2SC(CN3C4=CC=CC=C4SC(C3=O)CC(=O)O)=NC2=C1F BUYWFAJWTSIACV-UHFFFAOYSA-N 0.000 description 1
QKRGDZKQCDTVMW-UHFFFAOYSA-N 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]methyl]phthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2O1 QKRGDZKQCDTVMW-UHFFFAOYSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
229940093475 2-ethoxyethanol Drugs 0.000 description 1
FEIYMGHYGZJZCP-UHFFFAOYSA-N 2-ethoxyethyl 2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCCOCC)CC=CC2=C1 FEIYMGHYGZJZCP-UHFFFAOYSA-N 0.000 description 1
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
PYVSDYWCVCZXIY-UHFFFAOYSA-N 2-fluorospiro[fluorene-9,4'-imidazolidine] Chemical compound Fc1ccc2-c3ccccc3C3(CNCN3)c2c1 PYVSDYWCVCZXIY-UHFFFAOYSA-N 0.000 description 1
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
LDZYRENCLPUXAX-UHFFFAOYSA-N 2-methyl-1h-benzimidazole Chemical compound C1=CC=C2NC(C)=NC2=C1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
RIIVBOIBIOLLPO-UHFFFAOYSA-N 2-phthalazin-1-ylacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NN=CC2=C1 RIIVBOIBIOLLPO-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
PITVZRMNFBGRFW-UHFFFAOYSA-N 5,6-dichloro-1h-indole-2-carboxylic acid Chemical compound ClC1=C(Cl)C=C2NC(C(=O)O)=CC2=C1 PITVZRMNFBGRFW-UHFFFAOYSA-N 0.000 description 1
ROLKDXFFBNOIDS-UHFFFAOYSA-N 5,6-dihydroquinoline Chemical compound C1=CN=C2C=CCCC2=C1 ROLKDXFFBNOIDS-UHFFFAOYSA-N 0.000 description 1
NGHMKLRBKIPQRY-UHFFFAOYSA-N 5-butyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound CCCCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC2=NC=CC=C12 NGHMKLRBKIPQRY-UHFFFAOYSA-N 0.000 description 1
CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
ZWKXLNHOSNQZLS-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(1h-indazol-7-yl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=3NN=CC=3C=CC=2)C=1C1CC1 ZWKXLNHOSNQZLS-UHFFFAOYSA-N 0.000 description 1
HMCQXPJNWHQROJ-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)F)C=1C1CC1 HMCQXPJNWHQROJ-UHFFFAOYSA-N 0.000 description 1
GDXBRVCQGGKXJY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound NC(N)=NC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2)C=1C1CC1 GDXBRVCQGGKXJY-UHFFFAOYSA-N 0.000 description 1
LFOAPSAWYUILCY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-8-ylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=NC=CC=C3C=CC=2)C=1C1CC1 LFOAPSAWYUILCY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229940122614 Adenosine receptor agonist Drugs 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
UCUMZWHGNFCVTI-UHFFFAOYSA-N Cl.OC1=CC=CC2=C1N=NN2.CCN=C=NCCCN(C)C Chemical compound Cl.OC1=CC=CC2=C1N=NN2.CCN=C=NCCCN(C)C UCUMZWHGNFCVTI-UHFFFAOYSA-N 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
108020005199 Dehydrogenases Proteins 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
206010019668 Hepatic fibrosis Diseases 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
206010023421 Kidney fibrosis Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
LBBLDJJXDUQFQU-UHFFFAOYSA-N [C].[C].[C] Chemical compound [C].[C].[C] LBBLDJJXDUQFQU-UHFFFAOYSA-N 0.000 description 1
PFRUBEOIWWEFOL-UHFFFAOYSA-N [N].[S] Chemical compound [N].[S] PFRUBEOIWWEFOL-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002580 adenosine A3 receptor antagonist Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000005037 alkyl phenyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical group N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
150000005347 biaryls Chemical class 0.000 description 1
229960001035 bopindolol Drugs 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
XXPUICQZACXXNY-UHFFFAOYSA-N butyl 1-isoquinolin-5-yl-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCCCC)=CN1C1=CC=CC2=CN=CC=C12 XXPUICQZACXXNY-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
125000005111 carboxyalkoxy group Chemical group 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000000 cycloalkoxy group Chemical group 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
238000006193 diazotization reaction Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000012632 fluorescent imaging Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229950010772 glucose-1-phosphate Drugs 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
229960004569 indapamide Drugs 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229910052816 inorganic phosphate Inorganic materials 0.000 description 1
230000012105 intracellular pH reduction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000010016 myocardial function Effects 0.000 description 1
208000002089 myocardial stunning Diseases 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
VQQZGIHDTAZSIB-UHFFFAOYSA-N n-(diaminomethylidene)-3-methyl-1-naphthalen-1-ylpyrazole-4-carboxamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC2=CC=CC=C12 VQQZGIHDTAZSIB-UHFFFAOYSA-N 0.000 description 1
DIJXCEMJEZJHHT-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(1h-indazol-5-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(NN=C2)C2=C1 DIJXCEMJEZJHHT-UHFFFAOYSA-N 0.000 description 1
IAPMTJLFQONPMP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(2-methyl-3h-benzimidazol-5-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=C(C)N2)C2=C1 IAPMTJLFQONPMP-UHFFFAOYSA-N 0.000 description 1
VGSVDBBUTFVKKP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-phenylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC=C1 VGSVDBBUTFVKKP-UHFFFAOYSA-N 0.000 description 1
GAPSFQHYURAUOL-UHFFFAOYSA-N n-(diaminomethylidene)-5-methyl-2-quinolin-5-yltriazole-4-carboxamide Chemical compound N1=C(C(=O)NC(N)=N)C(C)=NN1C1=CC=CC2=NC=CC=C12 GAPSFQHYURAUOL-UHFFFAOYSA-N 0.000 description 1
IJZQRLYNEVAONK-UHFFFAOYSA-N n-(diaminomethylidene)-5-propan-2-yl-1-quinolin-6-ylpyrazole-4-carboxamide Chemical compound CC(C)C1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CC=C2)C2=C1 IJZQRLYNEVAONK-UHFFFAOYSA-N 0.000 description 1
YUZRJRZCWFSHBF-UHFFFAOYSA-N n-(diaminomethylidene)-5-propyl-1-quinolin-6-ylpyrazole-4-carboxamide Chemical compound CCCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CC=C2)C2=C1 YUZRJRZCWFSHBF-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
229940039748 oxalate Drugs 0.000 description 1
125000003585 oxepinyl group Chemical group 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
229960001085 piretanide Drugs 0.000 description 1
229950010884 ponalrestat Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
AMMGCGVWJMRTQI-UHFFFAOYSA-N prop-1-en-2-yl carbonochloridate Chemical compound CC(=C)OC(Cl)=O AMMGCGVWJMRTQI-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
208000022064 reactive hyperemia Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
229940107685 reopro Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 description 1
229950004311 sorbinil Drugs 0.000 description 1
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
229960003069 tolrestat Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
229960000537 xipamide Drugs 0.000 description 1
229950006343 zenarestat Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)

SK1234-2000A 1998-02-27 1999-02-05 Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie SK12342000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7636298P	1998-02-27	1998-02-27
PCT/IB1999/000206 WO1999043663A1 (en)	1998-02-27	1999-02-05	N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia

Publications (1)

Publication Number	Publication Date
SK12342000A3 true SK12342000A3 (sk)	2001-03-12

Family

ID=22131525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1234-2000A SK12342000A3 (sk)	1998-02-27	1999-02-05	Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie

Country Status (39)

Country	Link
US (2)	US6492401B1 (de)
EP (2)	EP1454902A1 (de)
JP (2)	JP2002504546A (de)
KR (4)	KR20030078886A (de)
CN (1)	CN1289326A (de)
AP (1)	AP9901478A0 (de)
AR (1)	AR015526A1 (de)
AT (1)	ATE286034T1 (de)
AU (1)	AU739403B2 (de)
BG (1)	BG104803A (de)
BR (1)	BR9908332A (de)
CA (1)	CA2321642A1 (de)
CO (1)	CO4980897A1 (de)
DE (1)	DE69922930T2 (de)
DK (1)	DK1056729T3 (de)
DZ (1)	DZ2729A1 (de)
EA (1)	EA003603B1 (de)
ES (1)	ES2237080T3 (de)
GT (1)	GT199900022A (de)
HR (2)	HRP20010666A2 (de)
HU (1)	HUP0204418A3 (de)
ID (1)	ID25505A (de)
IL (1)	IL136588A0 (de)
IS (1)	IS5548A (de)
NO (1)	NO20004192L (de)
NZ (1)	NZ504769A (de)
OA (1)	OA11450A (de)
PA (1)	PA8468401A1 (de)
PE (1)	PE20000334A1 (de)
PL (1)	PL342444A1 (de)
PT (1)	PT1056729E (de)
SI (1)	SI1056729T1 (de)
SK (1)	SK12342000A3 (de)
TN (1)	TNSN99028A1 (de)
TR (1)	TR200002480T2 (de)
TW (1)	TWI226329B (de)
WO (1)	WO1999043663A1 (de)
YU (1)	YU46200A (de)
ZA (1)	ZA991578B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002504546A (ja) *	1998-02-27	2002-02-12	ファイザー・プロダクツ・インク	虚血の治療のためのｎ−［（置換５員ジもしくはトリアザ二不飽和環）カルボニル］グアニジン誘導体
FR2795726A1 (fr) *	1999-06-30	2001-01-05	Aventis Cropscience Sa	Nouveaux pyrazoles fongicides
UA72002C2 (en) *	1999-10-29	2005-01-17	Pfizer Prod Inc	Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage
US6441176B1 (en)	1999-10-29	2002-08-27	Pfizer Inc.	Method for preparing sodium-hydrogen exchanger type 1 inhibitor
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6570013B2 (en)	2000-02-16	2003-05-27	Pfizer Inc	Salts of zopolrestat
US6555569B2 (en) *	2000-03-07	2003-04-29	Pfizer Inc.	Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
MXPA02010222A (es)	2000-04-18	2003-05-23	Agouron Pharma	Pirazoles para inhibir proteina cinasa.
AP2002002651A0 (en) *	2000-04-28	2002-12-31	Pfizer Prod Inc	Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
US6852733B2 (en) *	2000-04-28	2005-02-08	Pfizer Inc.	Sodium-hydrogen exchanger type 1 inhibitor
IL144507A0 (en) *	2000-07-31	2002-05-23	Pfizer Prod Inc	Use of glycogen phosphorylase inhibitors to inhibit tumor growth
EP1337508A1 (de) *	2000-11-28	2003-08-27	Pfizer Products Inc.	Verfahren zur herstellung eines natrium-wasserstoff-austauschers typ 1 inhibitor
IL147696A0 (en) *	2001-01-25	2002-08-14	Pfizer Prod Inc	Combination therapy
US6423705B1 (en)	2001-01-25	2002-07-23	Pfizer Inc.	Combination therapy
CA2436539A1 (en) *	2001-01-31	2002-08-08	Pfizer Products Inc.	Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
WO2002098429A1 (en) *	2001-06-07	2002-12-12	Pfizer Products Inc.	Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
US7358267B2 (en) *	2001-06-29	2008-04-15	Amgen Inc.	Bis-aryl thiazole derivatives
PL369074A1 (en) *	2001-11-02	2005-04-18	Aventis Pharmaceuticals Inc.	Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
BR0215002A (pt)	2001-12-19	2004-11-09	Pfizer Prod Inc	Métodos de preparação de inibidores de permutadores de sódio-hidrogênio de tipo 1
EP1472242A1 (de) *	2002-01-30	2004-11-03	Pfizer Products Inc.	Pharmazeutische zusammensetzungen, zoniporide mesylat enthaltend und prozesse zur verbesserung der löslichkeit von zoniporide
CA2483927A1 (en) *	2002-05-02	2003-11-13	Pfizer Products Inc.	Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
FR2840302B1 (fr) *	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842524B1 (fr) *	2002-07-16	2005-04-22	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
FR2842525B1 (fr) *	2002-07-16	2005-05-13	Aventis Pharma Sa	Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842526B1 (fr)	2002-07-16	2007-07-13	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
US7365070B2 (en) *	2002-12-04	2008-04-29	Ore Pharmaceuticals Inc.	Modulators of melanocortin receptor
ZA200505734B (en) *	2003-02-07	2006-12-27	Daiichi Seiyaku Co	Pyrazole Derivative
SG134333A1 (en)	2003-11-12	2007-08-29	Phenomix Corp	Heterocyclic boronic acid compounds
US7576121B2 (en)	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en)	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200526641A (en) *	2003-12-26	2005-08-16	Daiichi Seiyaku Co	Amidopyrazole derivatives
WO2005079803A1 (en) *	2004-02-13	2005-09-01	Pfizer Products, Inc.	Compounds for treatment of cardiovascular diseases
EP1778220A1 (de)	2004-07-12	2007-05-02	Phenomix Corporation	Eingezwängte cyano-verbindungen
US7223786B2 (en)	2004-11-15	2007-05-29	Bristol-Myers Squibb Company	2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en)	2004-11-15	2007-06-05	Bristol-Myers Squibb Company	2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en)	2004-11-15	2006-05-18	Bristol-Myers Squibb Company	2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
JP2008526816A (ja) *	2005-01-10	2008-07-24	デビオファームソシエテアノニム	心筋虚血状態の間の投与のための薬剤の製造のための環状ウンデカペプチドの使用
US20060235028A1 (en)	2005-04-14	2006-10-19	Li James J	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en)	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2046753A2 (de)	2006-07-06	2009-04-15	Brystol-Myers Squibb Company	Pyridon/hydroxypyridin-11-beta-hydroxysteroid-dehydrogenase-hemmer vom typ i
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2142551B1 (de)	2007-04-17	2015-10-14	Bristol-Myers Squibb Company	KONDENSIERTE HETEROCYCLISCHE Verbindungen als Hemmer der BETA-HYDROXYSTEROID-DEHYDROGENASE -TYP I
ES2408384T3 (es)	2007-07-27	2013-06-20	Bristol-Myers Squibb Company	Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
PT2294066E (pt) *	2008-04-28	2014-11-21	Janssen Pharmaceutica Nv	Benzoimidazoles como inibidores da prolil-hidroxilase
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
MX2011005221A (es) *	2008-11-21	2011-08-03	Raqualia Pharma Inc	Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
WO2010094090A2 (en) *	2009-02-18	2010-08-26	Katholleke Universiteit Leuven	Synucleinopathies
CN102971313A (zh)	2010-04-14	2013-03-13	百时美施贵宝公司	新颖的葡糖激酶激活剂及其使用方法
CN102408385B (zh) *	2011-06-20	2014-06-18	雅本化学股份有限公司	一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) *	2011-07-27	2014-05-07	雅本化学股份有限公司	2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
BR112014006940A2 (pt)	2011-09-23	2017-04-04	Bayer Ip Gmbh	uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas
WO2013063221A1 (en)	2011-10-25	2013-05-02	Janssen Pharmaceutica Nv	Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
WO2013130411A1 (en)	2012-02-27	2013-09-06	Essentialis, Inc.	Salts of potassium atp channel openers and uses thereof
AU2016301745B2 (en)	2015-08-06	2020-07-16	Ube Industries, Ltd.	Substituted guanidine derivative
WO2017057695A1 (ja) *	2015-09-30	2017-04-06	東レ株式会社	ジフェニルピラゾール誘導体及びその医薬用途
WO2017104741A1 (ja)	2015-12-16	2017-06-22	日本曹達株式会社	アリールアゾール化合物および有害生物防除剤
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2104931B1 (de) *	1970-09-08	1975-01-10	Ferlux
CA2121391A1 (en)	1993-04-28	1994-10-29	Atsuyuki Kojima	Indoloylguanidine derivatives
IL109570A0 (en) *	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0639573A1 (de) *	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en)	1993-08-03	1998-12-22	Hoechst Aktiengesellschaft	Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
DE4412334A1 (de)	1994-04-11	1995-10-19	Hoechst Ag	Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en) *	1994-10-18	1996-04-19	Masahumi Kitano	Indoloylguanidine derivatives
NZ314105A (en)	1996-02-02	1997-12-19	Sumitomo Pharma	Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
JPH09291076A (ja)	1996-04-24	1997-11-11	Sumitomo Pharmaceut Co Ltd	置換グアニジン誘導体およびその製法
ZA9711102B (en) *	1996-12-16	1998-08-13	Yamanouchi Pharma Co Ltd	N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative
JP2002504546A (ja) *	1998-02-27	2002-02-12	ファイザー・プロダクツ・インク	虚血の治療のためのｎ−［（置換５員ジもしくはトリアザ二不飽和環）カルボニル］グアニジン誘導体

1999
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Ceased
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Ceased
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active Expired - Fee Related
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active Expired - Fee Related
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Ceased
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 EP EP04008203A patent/EP1454902A1/de not_active Withdrawn
- 1999-02-05 EP EP99901083A patent/EP1056729B1/de not_active Expired - Lifetime
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192L/no not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69922930T2 (de)	2005-12-29
EP1454902A1 (de)	2004-09-08
IL136588A0 (en)	2001-06-14
US6492401B1 (en)	2002-12-10
PL342444A1 (en)	2001-06-04
CO4980897A1 (es)	2000-11-27
WO1999043663A1 (en)	1999-09-02
HRP20010666A2 (en)	2001-10-31
AU2070699A (en)	1999-09-15
EA003603B1 (ru)	2003-06-26
YU46200A (sh)	2003-02-28
HUP0204418A2 (hu)	2003-04-28
KR20010041397A (ko)	2001-05-15
TR200002480T2 (tr)	2000-12-21
AP9901478A0 (en)	1999-03-31
JP2002504546A (ja)	2002-02-12
AU739403B2 (en)	2001-10-11
DK1056729T3 (da)	2005-04-11
JP2005041879A (ja)	2005-02-17
ATE286034T1 (de)	2005-01-15
DZ2729A1 (fr)	2005-03-01
KR20030009548A (ko)	2003-01-29
NO20004192D0 (no)	2000-08-22
BR9908332A (pt)	2000-11-07
KR20030083004A (ko)	2003-10-23
AR015526A1 (es)	2001-05-02
KR100407903B1 (ko)	2003-12-01
OA11450A (en)	2003-12-04
EA200000789A1 (ru)	2001-02-26
KR20030078886A (ko)	2003-10-08
IS5548A (is)	2000-06-27
CA2321642A1 (en)	1999-09-02
TWI226329B (en)	2005-01-11
HUP0204418A3 (en)	2003-10-28
EP1056729B1 (de)	2004-12-29
PT1056729E (pt)	2005-04-29
NO20004192L (no)	2000-08-22
HRP20000550A2 (en)	2001-02-28
KR100449600B1 (ko)	2004-09-21
GT199900022A (es)	2000-08-15
DE69922930D1 (de)	2005-02-03
ID25505A (id)	2000-10-05
SI1056729T1 (en)	2005-04-30
ZA991578B (en)	2000-08-28
TNSN99028A1 (fr)	2005-11-10
US20030149043A1 (en)	2003-08-07
US6974813B2 (en)	2005-12-13
EP1056729A1 (de)	2000-12-06
ES2237080T3 (es)	2005-07-16
NZ504769A (en)	2005-04-29
CN1289326A (zh)	2001-03-28
PA8468401A1 (es)	2000-09-29
BG104803A (bg)	2001-05-31
PE20000334A1 (es)	2000-05-13

Publication	Publication Date	Title
SK12342000A3 (sk)	2001-03-12	Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie
US6403620B1 (en)	2002-06-11	Inhibitors of factor Xa with a neutral P1 specificity group
KR100569324B1 (ko)	2006-04-07	Ｈｉｖ 치료용 피라졸 유도체
KR20020034206A (ko)	2002-05-08	허혈증 치료용 화합물
CZ20032321A3 (en)	2004-03-17	Fused heterocyclic compounds
JPH11302277A (ja)	1999-11-02	ピラゾール誘導体、その製法および医薬としてのその使用
FI79103B (fi)	1989-07-31	Foerfarande foer framstaellning av terapeutiskt aktiva 1,4-dihydropyridinderivat.
CA2577420C (en)	2015-10-06	Lonidamine analogues and their use in male contraception and cancer treatment
WO2005090328A1 (ja)	2005-09-29	複素環化合物およびその用途
CA2494321C (en)	2009-01-06	1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
CN114846004B (zh)	2024-10-11	抗疟药
MXPA02010600A (es)	2003-03-10	Inhibidor del intercambiador de sodio-hidrogeno de tipo 1.
CZ20002988A3 (cs)	2000-11-15	Deriváty N-{(substituovaný pětičlenný di- nebo triaza-di-nenasycený kruh)karbonyl} guanidinu pro léčení ischemie
MXPA00008400A (en)	2001-07-09	N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia
AU779106B2 (en)	2005-01-06	Method for preparing sodium-hydrogen exchanger type 1 inhibitor
ES2305563T3 (es)	2008-11-01	Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih.
LT4702B (lt)	2000-09-25	Xa faktoriaus inhibitorius su neutralia p1 specifine grupe
LT4673B (lt)	2000-07-25	Azoto heteroaromatiniai junginiai kaip faktoriaus xa inhibitoriai